AKBA Key Statistics, Chart & Performance
The current stock price of AKBA is 1.66 USD. In the past month the price increased by 4.4%. In the past year, price decreased by -14.87%.
AKBA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About AKBA
Company Profile
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 181 full-time employees. The company went IPO on 2014-03-20. The firm's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Its HIF-based product candidates and other pipeline assets are being evaluated to target areas of unmet needs. Its product candidates include AKB-9090, AKB-10108, AKB-097 and praliciguat.
Company Info
AKEBIA THERAPEUTICS INC
245 First Street
Cambridge MASSACHUSETTS 02142 US
CEO: John P. Butler
Employees: 181
Phone: 16178712098
AKEBIA THERAPEUTICS INC / AKBA FAQ
What does AKBA do?
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 181 full-time employees. The company went IPO on 2014-03-20. The firm's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Its HIF-based product candidates and other pipeline assets are being evaluated to target areas of unmet needs. Its product candidates include AKB-9090, AKB-10108, AKB-097 and praliciguat.
Can you provide the latest stock price for AKEBIA THERAPEUTICS INC?
The current stock price of AKBA is 1.66 USD. The price decreased by -2.35% in the last trading session.
Does AKEBIA THERAPEUTICS INC pay dividends?
AKBA does not pay a dividend.
What is the ChartMill technical and fundamental rating of AKBA stock?
AKBA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How is the market expecting AKBA stock to perform?
11 analysts have analysed AKBA and the average price target is 5.51 USD. This implies a price increase of 231.81% is expected in the next year compared to the current price of 1.66.
Can you provide the growth outlook for AKEBIA THERAPEUTICS INC?
The Revenue of AKEBIA THERAPEUTICS INC (AKBA) is expected to grow by 58.44% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the ownership structure of AKEBIA THERAPEUTICS INC (AKBA)?
You can find the ownership structure of AKEBIA THERAPEUTICS INC (AKBA) on the Ownership tab.
AKBA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to AKBA. When comparing the yearly performance of all stocks, AKBA is a bad performer in the overall market: 87.82% of all stocks are doing better.
AKBA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to AKBA. AKBA has a medium profitability rating, but doesn't score so well on its financial health evaluation.
AKBA Financial Highlights
Over the last trailing twelve months AKBA reported a non-GAAP Earnings per Share(EPS) of -0.07. The EPS increased by 69.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.37% | ||
| ROE | -38.24% | ||
| Debt/Equity | 4.3 |
AKBA Forecast & Estimates
11 analysts have analysed AKBA and the average price target is 5.51 USD. This implies a price increase of 231.81% is expected in the next year compared to the current price of 1.66.
For the next year, analysts expect an EPS growth of 113.6% and a revenue growth 58.44% for AKBA